Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ENZN's Cash to Debt is ranked higher than
99% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. ENZN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ENZN' s 10-Year Cash to Debt Range
Min: 0.22  Med: 1.72 Max: No Debt
Current: No Debt
Equity to Asset 0.97
ENZN's Equity to Asset is ranked higher than
97% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ENZN: 0.97 )
Ranked among companies with meaningful Equity to Asset only.
ENZN' s 10-Year Equity to Asset Range
Min: -0.25  Med: 0.50 Max: 0.97
Current: 0.97
-0.25
0.97
Interest Coverage No Debt
ENZN's Interest Coverage is ranked higher than
99% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ENZN' s 10-Year Interest Coverage Range
Min: 0.24  Med: 3.48 Max: 9999.99
Current: No Debt
0.24
9999.99
F-Score: 8
Z-Score: 35.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 91.05
ENZN's Operating margin (%) is ranked higher than
99% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ENZN: 91.05 )
Ranked among companies with meaningful Operating margin (%) only.
ENZN' s 10-Year Operating margin (%) Range
Min: -111.06  Med: 1.55 Max: 92.36
Current: 91.05
-111.06
92.36
Net-margin (%) 99.96
ENZN's Net-margin (%) is ranked higher than
98% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ENZN: 99.96 )
Ranked among companies with meaningful Net-margin (%) only.
ENZN' s 10-Year Net-margin (%) Range
Min: -53.9  Med: 1.33 Max: 181.11
Current: 99.96
-53.9
181.11
ROE (%) 106.38
ENZN's ROE (%) is ranked higher than
99% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. ENZN: 106.38 )
Ranked among companies with meaningful ROE (%) only.
ENZN' s 10-Year ROE (%) Range
Min: -46.75  Med: 1.44 Max: 165.21
Current: 106.38
-46.75
165.21
ROA (%) 98.51
ENZN's ROA (%) is ranked higher than
100% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. ENZN: 98.51 )
Ranked among companies with meaningful ROA (%) only.
ENZN' s 10-Year ROA (%) Range
Min: -24.24  Med: 0.39 Max: 136.6
Current: 98.51
-24.24
136.6
Revenue Growth (3Y)(%) -9.00
ENZN's Revenue Growth (3Y)(%) is ranked lower than
59% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ENZN: -9.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ENZN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -40.6  Med: -5.35 Max: 95.5
Current: -9
-40.6
95.5
» ENZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ENZN Guru Trades in Q2 2014

George Soros 50,123 sh (New)
Jim Simons 1,118,184 sh (+15.04%)
Michael Price 748,200 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
Paul Tudor Jones 36,398 sh (unchged)
First Pacific Advisors 347,035 sh (unchged)
Charles Brandes 1,043,363 sh (-0.48%)
» More
Q3 2014

ENZN Guru Trades in Q3 2014

Jim Simons 1,573,384 sh (+40.71%)
Paul Tudor Jones 47,998 sh (+31.87%)
Carl Icahn 5,904,863 sh (unchged)
First Pacific Advisors 347,035 sh (unchged)
George Soros Sold Out
Charles Brandes 1,034,833 sh (-0.82%)
Michael Price 340,000 sh (-54.56%)
» More
Q4 2014

ENZN Guru Trades in Q4 2014

Jim Simons 1,806,684 sh (+14.83%)
Carl Icahn 5,904,863 sh (unchged)
Paul Tudor Jones 47,998 sh (unchged)
Michael Price Sold Out
Charles Brandes 1,031,923 sh (-0.28%)
First Pacific Advisors 23,626 sh (-93.19%)
» More
Q1 2015

ENZN Guru Trades in Q1 2015

Jim Simons 2,185,907 sh (+20.99%)
Charles Brandes 1,036,073 sh (+0.40%)
Carl Icahn 5,904,863 sh (unchged)
Paul Tudor Jones 47,998 sh (unchged)
First Pacific Advisors 23,626 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ENZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Enzon Pharmaceuticals Inc

Top Micro-Cap Picks From the Gurus
Much like small-cap stocks, micro caps (generally defined as capitalizations between $50-300 million) offer opportunities for very large growth, but also present significant risk and volatility. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 2.44
ENZN's P/E(ttm) is ranked higher than
96% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. ENZN: 2.44 )
Ranked among companies with meaningful P/E(ttm) only.
ENZN' s 10-Year P/E(ttm) Range
Min: 1.38  Med: 6.08 Max: 1354.17
Current: 2.44
1.38
1354.17
Forward P/E 3.03
ENZN's Forward P/E is ranked higher than
96% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. ENZN: 3.03 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 2.30
ENZN's PE(NRI) is ranked higher than
96% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. ENZN: 2.30 )
Ranked among companies with meaningful PE(NRI) only.
ENZN' s 10-Year PE(NRI) Range
Min: 1.37  Med: 7.22 Max: 1625
Current: 2.3
1.37
1625
P/B 1.80
ENZN's P/B is ranked higher than
86% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ENZN: 1.80 )
Ranked among companies with meaningful P/B only.
ENZN' s 10-Year P/B Range
Min: 0.95  Med: 2.16 Max: 13.17
Current: 1.8
0.95
13.17
P/S 2.22
ENZN's P/S is ranked higher than
86% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. ENZN: 2.22 )
Ranked among companies with meaningful P/S only.
ENZN' s 10-Year P/S Range
Min: 0.96  Med: 2.48 Max: 11.93
Current: 2.22
0.96
11.93
POCF 2.24
ENZN's POCF is ranked higher than
100% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. ENZN: 2.24 )
Ranked among companies with meaningful POCF only.
ENZN' s 10-Year POCF Range
Min: 1.3  Med: 9.77 Max: 85.4
Current: 2.24
1.3
85.4
EV-to-EBIT 1.21
ENZN's EV-to-EBIT is ranked higher than
93% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. ENZN: 1.21 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZN' s 10-Year EV-to-EBIT Range
Min: -1254.7  Med: -2.00 Max: 976.9
Current: 1.21
-1254.7
976.9
Shiller P/E 2.73
ENZN's Shiller P/E is ranked higher than
97% of the 109 Companies
in the Global Biotechnology industry.

( Industry Median: 49.43 vs. ENZN: 2.73 )
Ranked among companies with meaningful Shiller P/E only.
ENZN' s 10-Year Shiller P/E Range
Min: 1.71  Med: 8.30 Max: 43.92
Current: 2.73
1.71
43.92
Current Ratio 49.77
ENZN's Current Ratio is ranked higher than
98% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. ENZN: 49.77 )
Ranked among companies with meaningful Current Ratio only.
ENZN' s 10-Year Current Ratio Range
Min: 1.06  Med: 5.81 Max: 49.77
Current: 49.77
1.06
49.77
Quick Ratio 49.77
ENZN's Quick Ratio is ranked higher than
98% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ENZN: 49.77 )
Ranked among companies with meaningful Quick Ratio only.
ENZN' s 10-Year Quick Ratio Range
Min: 1.06  Med: 5.41 Max: 49.77
Current: 49.77
1.06
49.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.82
ENZN's Price/Net Cash is ranked higher than
94% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. ENZN: 1.82 )
Ranked among companies with meaningful Price/Net Cash only.
ENZN' s 10-Year Price/Net Cash Range
Min: 1.39  Med: 19.71 Max: 343.75
Current: 1.82
1.39
343.75
Price/Net Current Asset Value 1.79
ENZN's Price/Net Current Asset Value is ranked higher than
94% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. ENZN: 1.79 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ENZN' s 10-Year Price/Net Current Asset Value Range
Min: 1.38  Med: 12.74 Max: 80.32
Current: 1.79
1.38
80.32
Price/Tangible Book 1.66
ENZN's Price/Tangible Book is ranked higher than
88% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. ENZN: 1.66 )
Ranked among companies with meaningful Price/Tangible Book only.
ENZN' s 10-Year Price/Tangible Book Range
Min: 1.28  Med: 9.21 Max: 412.5
Current: 1.66
1.28
412.5
Price/Projected FCF 0.94
ENZN's Price/Projected FCF is ranked higher than
94% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ENZN: 0.94 )
Ranked among companies with meaningful Price/Projected FCF only.
ENZN' s 10-Year Price/Projected FCF Range
Min: 0.44  Med: 1.36 Max: 56.41
Current: 0.94
0.44
56.41
Price/Median PS Value 0.90
ENZN's Price/Median PS Value is ranked higher than
66% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. ENZN: 0.90 )
Ranked among companies with meaningful Price/Median PS Value only.
ENZN' s 10-Year Price/Median PS Value Range
Min: 0.53  Med: 2.06 Max: 58.93
Current: 0.9
0.53
58.93
Price/Graham Number 0.40
ENZN's Price/Graham Number is ranked higher than
98% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.52 vs. ENZN: 0.40 )
Ranked among companies with meaningful Price/Graham Number only.
ENZN' s 10-Year Price/Graham Number Range
Min: 0.31  Med: 1.98 Max: 91.67
Current: 0.4
0.31
91.67
Earnings Yield (Greenblatt) (%) 81.45
ENZN's Earnings Yield (Greenblatt) (%) is ranked higher than
98% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ENZN: 81.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENZN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 9.40 Max: 359
Current: 81.45
0.1
359

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EZ1.Germany,
Enzon Pharmaceuticals Inc is a biotechnology company. The Company is related to sales of six marketed drug products namely, PegIntron, Sylatron, Macugen, CIMZIA, Oncaspar and Adagen. The Company generates revenues from the royalty from the sales of PegIntron marketed by Merck & Co., Inc. The Company has a strategic alliance with Zhejiang Hisun Pharmaceuticals Co. Ltd development and commercialization rights for PEG-SN38 in China.
» More Articles for ENZN

Headlines

Articles On GuruFocus.com
Top Micro-Cap Picks From the Gurus Jun 23 2015 
icahn May 27 2015 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
GuruFocus Real Time Picks of the Week Jan 10 2014 
Seth Klarman Buys New Stock Kindred Biosciences, Cut Stake in Enzon Jan 10 2014 
Billionaires Hold Bargains, 40% Off or More Sep 11 2013 
Charles Brandes Top Second Quarter Portfolio Changes Aug 09 2013 
First Pacific Advisors’ Top New Buys Aug 08 2012 
Enzon Inc. Reports Operating Results (10-K) Mar 16 2011 
Carl Icahn Buys NAV, CHK, ENZN, AMLN, CMC, Feb 15 2011 

More From Other Websites
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 08 2015
Enzon Pharmaceuticals Inc (ENZN)’s Shares Rally After Special Cash Dividend Announcement Jul 06 2015
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Jul 02 2015
ENZON PHARMACEUTICALS INC Financials May 22 2015
10-Q for Enzon Pharmaceuticals, Inc. May 15 2015
ENZON PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 13 2015
Nasdaq stocks posting largest volume increases Apr 29 2015
Most active Nasdaq-traded stocks Apr 29 2015
Voltari Corp (VLTC): Carl Icahn Stirring Yet Another Pot Apr 01 2015
ENZON PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 05 2015
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events Dec 10 2014
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events Dec 05 2014
ENZON PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 06 2014
DELiA*s Rebounds As Reports Suggest Delisting May Be Imminent Nov 03 2014
Bankruptcy Filing Fallout Continues For NII Holdings Sep 19 2014
ENZON PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 16 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK